SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Entry into a Material Definitive Agreement

SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Entry into a Material Definitive Agreement
Item 9.01Entry into a Material Definitive Agreement

Story continues below

On October 13, 2017, Spectrum Pharmaceuticals, Inc. (the “Company”) entered into the First Amendment (the “Amendment”) to the Company’s Rights Agreement, dated as of December 13, 2010 (the “Rights Agreement), by and between the Company and Computershare Trust Company, N.A. (the “Rights Agent”). to Section 27 of the Rights Agreement, the Company amended the Rights Agreement to add the defined term “Designated Holder” for the purpose of providing a limited exemption to a specified institutional investor and its subsidiaries and affiliates (collectively, the “Investor”) from the definition of “Acquiring Person” under the Rights Agreement. This limited exemption permits the Investor to become the beneficial owner of up to 19.99% of the common shares of the Company then outstanding without becoming an Acquiring Person (as defined in the Rights Agreement) rather than the 14.99% threshold otherwise applicable. The Investor will be deemed a Designated Holder until the earliest of (a) such time as the Investor ceases to beneficially own 10% or more of the common shares of the Company, (b) the specified institutional investor or any parent entity is subject to a change of control or (c) the Investor reports or is required to report on Schedule 13D (or any successor or comparable report) its beneficial ownership of common shares of the Company. The foregoing description of the Amendment is qualified in its entirety by reference to the applicable provisions of the Amendment, which is filed as Exhibit 4.1 hereto and incorporated herein by reference.

Item 9.01Material Modification to Rights of Security Holders

The description of the Amendment to the Rights Agreement set forth above under Item 9.01 “Entry Into a Material Definitive Agreement” is incorporated into this Item 9.01 by reference.

Item 9.01Financial Statements and Exhibits


SPECTRUM PHARMACEUTICALS INC Exhibit
EX-4.1 2 ex41-firstamend.htm EXHIBIT 4.1 Exhibit FIRST AMENDMENT TO RIGHTS AGREEMENTThis First Amendment to Rights Agreement (this “Amendment”) is dated as of October 13,…
To view the full exhibit click here

About SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI)

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.

An ad to help with our costs